title: Rubinstein-Taybi syndrome - a window into follicular lymphoma biology.
authors.affiliation: a Division of Hematology/Oncology , University of California Irvine , Orange , CA , USA.
authors.forename: Nataliya
authors.initials: N
authors.lastname: Mar
authors.affiliation: b Department of Pathology , Hartford Hospital , Hartford , CT , USA.
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Digiuseppe
authors.affiliation: c Department of Hematology/Oncology , Hartford Hospital , Hartford , CT , USA.
authors.forename: Mark E
authors.initials: ME
authors.lastname: Dailey
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050882:CREB-Binding Protein / Q000235:genetics; D003520:Cyclophosphamide / Q000627:therapeutic use; D004252:DNA Mutational Analysis; D000071221:Enhancer of Zeste Homolog 2 Protein / Q000235:genetics; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D006801:Humans; D008207:Lymphatic Metastasis; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology*; D011241:Prednisone / Q000627:therapeutic use; D053240:Receptors, Tumor Necrosis Factor, Member 14 / Q000235:genetics; D000069283:Rituximab / Q000008:administration & dosage; D012415:Rubinstein-Taybi Syndrome / Q000150:complications* / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D053240:Receptors, Tumor Necrosis Factor, Member 14; C506028:TNFRSF14 protein, human; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D050882:CREB-Binding Protein; C494363:CREBBP protein, human; D011241:Prednisone